ncRNA basic information ncRNA ID: MI0000293 ncRNA Database: miRBase ncRNA Name: miR-217 ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: qPCR ncRNA Target Gene: KRAS ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00997 (APRD00185, DB05331, DB05847) Drug Name: Doxorubicin Drug Method: The expression of miR-217 was determined by quantitative polymerase chain reaction (qPCR). Following transfection with miR-217 mimics, an MTT assay, chemosensitivity assay, cell apoptosis assay and western blot analysis were performed in AML cell lines. Functional assays were also performed to explore the effects of endogenous Kirsten rat sarcoma viral oncogene homolog (KRAS) in AML. The results revealed that miR-217 was downregulated in patients with AML. Overexpression of miR-217 inhibited cellular proliferation and enhanced cell chemosensitivity to doxorubicin by the cell apoptosis pathway in AML cells. A dual-luciferase reporter assay demonstrated that KRAS was a direct target gene of miR-217 in vitro. qPCR and western blot analysis revealed that miR-217 negatively regulated KRAS protein expression, but had no impact on KRAS mRNA expression. Knockdown of KRAS expression markedly suppressed AML cellular proliferation, and enhanced cell chemosensitivity to doxorubicin via the cell apoptosis pathway. These findings indicate that miR-217 functions as a tumor suppressor in AML by directly targeting KRAS. Drug Response: sensitive

Cancer basic information Cancer: acute myeloid leukemia Tissue/Cell: cell line ( HL-60,K562)

Other information Title: MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS. Journal: Oncol Lett Published: 2017 PubMed ID: 28599501